Suppr超能文献

肺癌中p-STAT3过表达与预后的相关性:一项系统评价和荟萃分析。

Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis.

作者信息

Tong Mengting, Wang Jing, Jiang Nanyu, Pan Hongming, Li Da

机构信息

Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

出版信息

PLoS One. 2017 Aug 10;12(8):e0182282. doi: 10.1371/journal.pone.0182282. eCollection 2017.

Abstract

OBJECTIVE

Previous studies have shown the correlation between p-STAT3 overexpression and prognosis in a variety of human tumors. However, their correlation in lung cancer remains controversial. We performed a systematic review and meta-analysis to explore the correlation between p-STAT3 overexpression and prognosis in lung cancer patients.

METHODS

We searched PubMed, Embase, Web of Science, CNKI, VIP, and WanFang Data to identify relevant studies. Two reviewers independently screened the literature search results, extracted data, and assessed the methodological quality of the included studies. Then, meta-analysis was performed by using Review Manager 5.3 and STATA 14 software. A random-effect model was employed to evaluate all related pooled results. Statistical heterogeneity of each study was assessed by I2. Publication bias was determined by funnel plot and the Begg's or Egger's tests.

RESULTS

Eventually, 13 studies were included in present meta-analysis. Among these 13 studies, 8 studies were associated with the overall survival of lung cancer and 10 studies with other clinicopathological characteristics. The results of this meta-analysis suggested that p-STAT3 overexpression may be a poor prognosis biomarker in lung cancer (HR: 1.23; 95% CI: 1.04-1.46; P = 0.02). In terms of other clinicopathological characteristics, p-STAT3 overexpression was more frequent to advanced TNM stages ranging from III to IV (OR: 1.92; 95% CI: 1.13-3.27; P = 0.02) and lymphatic node metastasis (OR: 1.81; 95% CI: 1.20-2.72; P = 0.004). But, it was not associated with tumor differentiation (OR: 0.82; 95% CI: 0.44-1.53; P = 0.54).

CONCLUSION

p-STAT3 overexpression has significant correlation with poorer overall survival of lung cancer patients, as well as with more advanced TNM stages and lymph node metastasis. Thus, it may serve a biomarker for poor prognosis in lung cancer. Nevertheless, our findings should be confirmed by large prospective studies.

摘要

目的

既往研究已表明p-STAT3过表达与多种人类肿瘤的预后之间存在相关性。然而,它们在肺癌中的相关性仍存在争议。我们进行了一项系统评价和荟萃分析,以探讨p-STAT3过表达与肺癌患者预后之间的相关性。

方法

我们检索了PubMed、Embase、Web of Science、中国知网、维普资讯和万方数据,以识别相关研究。两名评价者独立筛选文献检索结果,提取数据,并评估纳入研究的方法学质量。然后,使用RevMan 5.3和STATA 14软件进行荟萃分析。采用随机效应模型评估所有相关的汇总结果。通过I²评估每项研究的统计异质性。通过漏斗图以及Begg检验或Egger检验确定发表偏倚。

结果

最终,13项研究纳入了本荟萃分析。在这13项研究中,8项研究与肺癌的总生存期相关,10项研究与其他临床病理特征相关。本荟萃分析结果表明,p-STAT3过表达可能是肺癌预后不良的生物标志物(HR:1.23;95%CI:1.04-1.46;P=0.02)。就其他临床病理特征而言,p-STAT3过表达在III至IV期的晚期TNM分期(OR:1.92;95%CI:1.13-3.27;P=0.02)和淋巴结转移(OR:1.81;95%CI:1.20-2.72;P=0.004)中更常见。但是,它与肿瘤分化无关(OR:0.82;95%CI:0.44-1.53;P=0.54)。

结论

p-STAT3过表达与肺癌患者较差的总生存期以及更晚期的TNM分期和淋巴结转移显著相关。因此,它可能作为肺癌预后不良的生物标志物。然而,我们的研究结果应通过大型前瞻性研究加以证实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff74/5552221/21708919adfc/pone.0182282.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验